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~903-11] AngiopiasWinAcuteMYOCardiallnfarctiOnin
ClinicaiPractice:Reeuitsin4625PatiantsFromtha
ALKKAngioplastyRegietry
R. Zahn, A. Vogt, K.-L. Neuhaus, S. Schuster, J. Senges for the ALKK
Study Group. Herzzerttrum Ludwigsfrafen, Germany
Angioplasly (A-AMI) has shown to be an effective therapy in patients (pt.)
with acute myocardial infarction (AMI). However, numbers of pt. treated
with A-AMI are still small and little is known about the use of A-AMI outside
highly specialized centers. We therefore analyzed thedataof the angioplaafy
ragistryof the ALKK, a group of non university hoepitalsin Germany.Behyeen
10/92 and 1295 a total of 81724 angioplastias were registered, including
4625 (5.7%) A-AMI. There were 75.1% men and the mean age was 61 +11
yeara (21-89 Y).Total occlusions of the infarct related artery were present in
3259 (70.5%)andastenosis 290% in874 (18.9%)pt. Tachnicalaucceasrate,
defined as stenosis after A-AMl < 50% WSS86%,and 5% showed a reaidual
stenosis of 250% and 40$’.. Additional thrombolysia wee given in 417 (9%)
pt. and stents were implanted in 443 (9.6%) pt. Bypass aurgery following PA
wee performed in 139 (3%) pt. Total hospital mortality was 9.6% (438 pt.).
There was a higher monallty in hospitals patforming s 40 A-AMI/year aa
compared to those with =-40 A-AMI/year (11.4% versus 8.1%, OR = 1.59,
95°ACl = 1.3&l .95). CorWrs/on: Inclinical pracfice A-AMl can bepetformad
with a high promcfurei success rate. Mortality in this multi-center registrywas
similar to that reported by large single oenter registries.
D90312 DiscrepancyBetweenActualvs.PotentialTreatmentinAcuteMyocardiainfsrotion:Useof
Thrombolytics,Aspirin,Bets-blockersand
ACE-inhibitorsinGermany1996.MITRAStudy
S.Schuster, U. Burczyk, R. Schiele, R. Zahn, A. Koch, H.G. Glunz,
U. Gieseler, J. Senges for the MITRA-StudyGrouP. Herzzentnrrn
Ludwigshafen, Germany
Tha aim of this study is to document actual clinical practice (pilot-phase)
and to improve the therapy of acute Ml individually according to published
recommendations. In the study phase, we used an educational program for
pstticipants. They were advised to consider only major contraindications for
each prognostically important drug.
MITRA isagerman registry of 54 hoepitals in tha Southwest. The total pts.
group consisted of 4178 patients with proven q-wave myooardial infarction.
Patients were documented consecutively and were enrolled even up to 96
hours after onset of aymptoms. Median age was 66 yeara, prehospitel delay
2.7 h, anterior Ml 48%, previous infarction 17.47..
Pilot-phase(n= 1303) Study phase (n= 2S75)
Pts. without Pm actualtreated Pta without Pts.actualtreated
contraindic. “ (%) ccmtraindic. “
(%) (%)
(%)
Thrombolysis 56.6 602 53.4 79.1 1373 60.4
Aspirin 99.7 1138 87.6 99.3 2724 95.4
p-Blocker 84.0 408 37.1 S2.6 1543 65.0
ACE-inhibit. 86.7 197 17.4 34.6 1559 64.1
Primary PTCA increased from 8.3% (pilot) to 11.4%(study phase).
Conclusion: Pharmacological therapy in acute Ml is inconsistent with the
recommendations of racent clinical trials as documented in the pilot phaae.
An individually optimized therapeutic concept, which considers only major
contraindications for each drug improves infarction therapy particularly for
beta-blocker and ACE-inhibitor.
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D90425 UnprouxtedLeftMainStanting:PreliminaryResuitaandFollow-upwiththe Firat41 Patients
M. Silvestri, P.Barragan, J.B. Sim60ni, P.O.Roquabert, G. Bayat,
J. Sainsous. Centre Carr.lio-VasculaireLas Alpilles, Marseille, France
Unprotected left main coronary artery (LMCA) angioplasty has been associ-
ated with a high procedural complication rate and short-term mortality. The
availability of etente and their success in reducing acute complications and
restenoeis may cause to re-examine the role of PTCA for LMCA disease.
Unprotected LMCA stent implantation was petformed electively in 41 con-
secutive patients (pts) included 20 poor candidate (group 1) and 21 god
candidates for CABG (group 2). Clinical data were in group 1: 15 males,
mean aga of 70 + 7 years, 10 pts with unstable angina (UA), mean LVEF
of 47 + 15%, 13 pts with prior cardiac surge~ and in group 2: 17 males,
mean age of 63 * 11 years, 11 pts with UA, mean LVEF of 64 + 11%. All
pts were treated with Ticlopidine (2 x 250 mg daily) etarted 3 days before
PTCA. Indications for atenting were elective for 39 pts and dissection for 2
pts. Angiographlc success was achieved in all pte with 54 stents (38 Paimez-
Schatz, 7 Gianturm-Roubin, 5 Saint-Come, 3 AVE and 1 Multi-Link stertta).
PTCA of 42 other vessels (inciuding 9 right cmonary artery) were alao dona
with 7 other stent implantations. Two subacute thrombosis occurred during
hospital stay in group 1, involving 2 deaths (4.7%). Nocardiacevent occurred
in group 2. Clinical follow-up was available in all pts (mean Interval of 13 +
IO months) ss foliow: 1 death in group 1, repeat LMCA PTCA for angina,
recurrence in 3 pts (177.) of group 1 and in 1 pt (5%) of group 2. Conokrsiom
Unprotected LMCA stenting with a 17clopidine regimen can be considered
as a safe and effective percutaneous intervention in selected pts. Neverths-
iess randomized trtais LMCA stenting versus surgety are necessary in good
candidates for CABG.
- StentingofWnprotscted-LeflMalnCoronary
ArteryStenosas:EariyandLateReaulta
C.J.J. Leruelle, G.B.R. Brueren, E.T.Ss1,S.M.P.G. Ernst, G.E. Maat,
M.-J. Suttorp, A.B. de la Riviere, H.W.T.Plokker. Depts of Cwdio/ogy&md
Cardiothoracic Surgery StAntonius Hospital, Nieuwegein, NL
Efackgrourrd:Transluminai angioplasfy of “unprotected” left main ooronary
artery (LMCA) stenosis is still considered to be contraindicated even in the
age of stenting.
Objectives: We reviewed the results of coronary stent (S) implantation in
“unprotected” LMCA stenosis in 18 consecutive patients (10 eleclive proce-
dures, 8 acute procedures)to asses shofl and iong-term effectiveness of this
procedure.
Popu/atiorr: Mean age was 70.8 yearn (range 36 to 91). Twelve men.
Fourteen pts had normal left ventricular function. Sevan patients had only a
significant lesion in the LMCA.
Results: Successful S-implantation was achieved in all patients with a
maximum balloon inflation preasure of at least 16 atmoapheree and a mean
maximum balloon size of 4.3 mm. Six pta underwent additional angiopiasty
of other atenoaea during the procedure. No major cardiac evente (acute
myocardial infarction, cardiac death, corona~ artery bypass aurgary, repeat
angiopiaety) occurred during tha procedure in the eiective group. In the
emergency group, one pt died, one pt underwent emergency coronary artety
bypaaeaurgery,one ptdeveloped a non q wave myocerdial infarction. During
hospital stay, one pt underwent a rapeat angioplasty in the elective group,
and one pt in the emergency group died suddeniy. Follow-up wee obtained
in all suwiving pts, at a mean interval of 9 monthe, there were 2 non related
death; one pt had clasa 2 angina and 12 pte had no eymptoms.
Conclusion: We mnclude that stent implantation in “unprotected” LMCA
stenosis using high pressure for S-delivaw can be conaiderad a safe and
effective coronary revaeculanzation option in selected patients in eiective
conditions. The short-term prognosis in emergency situations remains poor.
e] stentimP,an~tion Afiersucceesfui~a,,oo.
Angiopiaetyof a ChronicCoronaryOcclusion- A
RandomizedTriai
H. Sieverf’, S. Rohdel, R. Schulze2, A. Utech3, R. Eneelen1, H. Spies’,
D. Schererl, R. Schr~der, H. Merle, A. Fach 1.1 Cardiovascular Center
Bethanian CCB, Frankfurt, Gerrnan~ 2Klinik Dr Haerec U/m, Gerrnan~
3Rot-Kreuz Krankenhaus, Kassal, Germany
The restenosis rate after angioplasty for chronic totai coronary occlusion is
much higher compared to coronary stenoses. The benefit of etent implanta-
tion in this situation ia unknown.
60 Patiente were randomized after successful ballocm angioplasty of a
chroniccoronaryocclusionto’’stent” implantation orto ”nostent.” The bsaeline
characteristics of both groups showed no difference. Follow-up angiogram
was performed after4 monthaor earlier if necesaa~ for clinical reaaona.
Nostent Stent D
MLD (mm) 1.75 2.69 <0.001
‘/oStenosis 21.6 5.s <0.001
Reocdusion(%) 12 0 n,s.
Reetenoais>50”A 64 28 < 0.05
Re-PTCA orCABG (%) 52 24 < 0.05
ML04 months(mm) 0.95 1.s5 <0.01
O/.Stenosia4 months 61 33 <0.01
